Objective:To analyze application effects of Bevacizumab combined with chemotherapy in patients with non-small cell lung cancer(NSCLC).Methods:The clinical data of 68 patients with NSCLC admitted to this hospital from November 2021 to October 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,34 cases in each group.The control group was treated with Pemetrexed+Cisplatin chemotherapy,while the observation group was treated with Bevacizumab on the basis of that of the control group.The disease control rate(DCR),the levels of tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 125(CA125)]and T cell subsets(CD3+,CD4+,CD4+/CD8+)before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The DCR of the observation group was 85.29%(29/34),which was higher than 58.82%(20/34)of the control group,and the difference was statistically significant(P＜0.05).After the treatment,the levels of CEA,CYFRA21-1 and CA125 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).After the treatment,the levels of CD3+,CD4+,CD4+/CD8+in the two groups were lower than those before the treatment,but those in the observation group were higher than those in the control group,and the differences were statistically significant(P＜0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusions:Bevacizumab combined with chemotherapy can improve the DCR of the NSCLC patients,reduce the levels of tumor markers,and improve the levels of T cell subsets.Moreover,it is superior to simple chemotherapy.
关键词
非小细胞肺癌/贝伐珠单抗/化疗/疾病控制率/肿瘤标志物/T细胞亚群
Key words
Non-small cell lung cancer/Bevacizumab/Chemotherapy/Disease control rate/Tumor marker/T cell subsets
维普
万方数据